{"denoms":[{"counts":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"259"},{"groupId":"BG002","value":"170"},{"groupId":"BG003","value":"595"}],"units":"Participants"}],"groups":[{"description":"Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.","id":"BG000","title":"Arm A: Pembrolizumab + Surgery"},{"description":"Participants receive standard of care surgery alone.","id":"BG001","title":"Arm B: Surgery Alone"},{"description":"Participants receive 3 preoperative cycles of EV + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative EV + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.","id":"BG002","title":"Arm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.9","value":"71.8"},{"groupId":"BG001","spread":"7.7","value":"71.9"},{"groupId":"BG002","spread":"7.9","value":"72.1"},{"groupId":"BG003","spread":"7.8","value":"71.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"135"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"193"},{"groupId":"BG002","value":"137"},{"groupId":"BG003","value":"460"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"26"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"231"},{"groupId":"BG002","value":"160"},{"groupId":"BG003","value":"546"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"23"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"85"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"205"},{"groupId":"BG002","value":"132"},{"groupId":"BG003","value":"485"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"11"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"6"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"163"},{"groupId":"BG001","value":"223"},{"groupId":"BG002","value":"142"},{"groupId":"BG003","value":"528"}],"title":"Cisplatin-Ineligible"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"67"}],"title":"Cisplatin-Eligible but Declined"}]}],"description":"Particpants were categorized according to their cisplatin status: ineligible for cisplatin-based chemotherapy or eligible for but declined cisplatin-based chemotherapy","paramType":"COUNT_OF_PARTICIPANTS","title":"Cisplatin Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"82"}],"title":"T2N0"},{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"209"},{"groupId":"BG002","value":"133"},{"groupId":"BG003","value":"492"}],"title":"T3/T4aN0"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"21"}],"title":"T1-4aN1"}]}],"description":"Imaging of the chest, abdomen, and pelvis was performed within ≤28 days before randomization to assess tumor status as follows: T2N0: Stage II; tumor invades muscularis propria, no regional nodes, and generally has better outcomes. T3/T4aN0: Stage III; extends into perivesical tissue or adjacent organs, no regional nodes, and has worse outcomes. T1-4aN1: Stage III; tumor with one regional lymph node metastasis, generally associated with the worst outcomes. Disease staging was assessed centrally after review of the pathology and imaging results.","paramType":"COUNT_OF_PARTICIPANTS","title":"Tumor Clinical Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"73"}],"title":"United States (US)"},{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"78"},{"groupId":"BG003","value":"261"}],"title":"European Union (EU)"},{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"71"},{"groupId":"BG003","value":"261"}],"title":"Most of World (MOW)"}]}],"description":"Participants were categorized according to their geographic region (United States, European Union, or Most of World)","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"}]}